Hypertriglyceridemia: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Robert Badgett
No edit summary
imported>Robert Badgett
No edit summary
Line 7: Line 7:
"Patients in whom triglycerides >500 mg/dL should receive strict diet therapy including avoidance of alcohol, restriction of dietary fat, and avoidance of concentrated carbohydrates (sweets). For triglycerides >1000 mg/dL a very low fat diet should be instituted quickly to reduce chylomicronemia and risk of acute pancreatitis"
"Patients in whom triglycerides >500 mg/dL should receive strict diet therapy including avoidance of alcohol, restriction of dietary fat, and avoidance of concentrated carbohydrates (sweets). For triglycerides >1000 mg/dL a very low fat diet should be instituted quickly to reduce chylomicronemia and risk of acute pancreatitis"


More recently, "the combination of fenofibrate and simvastatin did not reduce the rate of fatal cardiovascular events, nonfatal myocardial infarction, or nonfatal stroke, as compared with simvastatin alone" according to a [[randomized controlled trial]]. <ref name="pmid20228404">{{cite journal| author=ACCORD Study Group. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA et al.| title=Effects of combination lipid therapy in type 2 diabetes mellitus. | journal=N Engl J Med | year= 2010 | volume= 362 | issue= 17 | pages= 1563-74 | pmid=20228404 | url=http://www.nejm.org/doi/full/10.1056/NEJMoa1001282}}</ref>
Regarding treating triglycerides amont diabetics with levels less than 650 mg/dl, "the combination of fenofibrate and simvastatin did not reduce the rate of fatal cardiovascular events, nonfatal myocardial infarction, or nonfatal stroke, as compared with simvastatin alone" according to a [[randomized controlled trial]]. <ref name="pmid20228404">{{cite journal| author=ACCORD Study Group. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA et al.| title=Effects of combination lipid therapy in type 2 diabetes mellitus. | journal=N Engl J Med | year= 2010 | volume= 362 | issue= 17 | pages= 1563-74 | pmid=20228404 | url=http://www.nejm.org/doi/full/10.1056/NEJMoa1001282}}</ref> However, among the diabetics with triglycerdies about 204 and HDL less than 34, there was significant better (primary outcome over 5 years reduced from 17% to 12%).<ref name="pmid20228404"/>


==References==
==References==
<references/>
<references/>

Revision as of 09:35, 28 June 2011

In medicine hypertriglyceridemia is a dyslipidemia and is "a condition of elevated levels of triglycerides in the blood".[1]

One cause is hypoalphalipoproteinemia.

Treatment

Clinical practice guidelines state:[2] "Patients in whom triglycerides >500 mg/dL should receive strict diet therapy including avoidance of alcohol, restriction of dietary fat, and avoidance of concentrated carbohydrates (sweets). For triglycerides >1000 mg/dL a very low fat diet should be instituted quickly to reduce chylomicronemia and risk of acute pancreatitis"

Regarding treating triglycerides amont diabetics with levels less than 650 mg/dl, "the combination of fenofibrate and simvastatin did not reduce the rate of fatal cardiovascular events, nonfatal myocardial infarction, or nonfatal stroke, as compared with simvastatin alone" according to a randomized controlled trial. [3] However, among the diabetics with triglycerdies about 204 and HDL less than 34, there was significant better (primary outcome over 5 years reduced from 17% to 12%).[3]

References

  1. Anonymous (2024), Hypertriglyceridemia (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. [Management of Dyslipidemia Working Group. VA/DoD clinical practice guideline for the management of dyslipidemia. Washington (DC): Department of Veterans Affairs, Department of Defense; 2006. 140 p.
  3. 3.0 3.1 ACCORD Study Group. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA et al. (2010). "Effects of combination lipid therapy in type 2 diabetes mellitus.". N Engl J Med 362 (17): 1563-74. PMID 20228404.